NHS to offer 'groundbreaking' sickle cell therapy

NHS England to offer Casgevy for sickle cell disease patients
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by approval for transfusion-dependent beta-thalassemia (TDT) in January 2024. NHS England reached an earlier reimbursement agreement for Casgevy in TDT in August 2024.
Sickle cell disease ‘cure’ to be offered to NHS patients
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant
Sickle cell patients share delight over approval of new treatment
NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain patients with severe sickle cell disease. Here patients have reacted to the news:
NHS to offer 'groundbreaking' sickle cell gene therapy
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts say.
NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) gene therapy to treat a severe form of sickle cell disease (SCD).
NHS to offer 'groundbreaking' sickle cell therapy as patients given 'very real prospect of cure'
A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use on the NHS in England. The one-time treatment, called Casgevy (exa-cel), has shown remarkable success in clinical trials,
Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients
Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with
'Groundbreaking' sickle cell treatment to be offered to NHS patients for first time
It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will receive it.
£1.65m gene-editing therapy offers hope of cure for some blood disorder patients
A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder hope of a cure. Campaigners reacted with joy as health officials approved a gene-editing therapy for certain children and adults with severe sickle cell disorder.
UK health system to offer cutting-edge gene therapy for sickle cell disease
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.
Revolutionary gene-editing therapy for sickle cell approved
NHS Karla Sofia Gascón apologizes for old tweets, says she is 'deeply sorry to those I have caused pain' Everything we know about China's new 6th gen fighter jet... AstraZeneca cancels £450m investmen
People living with Sicke Cell apprehensive of new treatment Casgevy being here to stay
People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...
STAT1d
Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...